251 related articles for article (PubMed ID: 22457633)
21. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance.
Jern P; Russell RA; Pathak VK; Coffin JM
PLoS Pathog; 2009 Apr; 5(4):e1000367. PubMed ID: 19343218
[TBL] [Abstract][Full Text] [Related]
22. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).
Pillai SK; Wong JK; Barbour JD
Retrovirology; 2008 Mar; 5():26. PubMed ID: 18339206
[TBL] [Abstract][Full Text] [Related]
23. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G.
Ikeda T; Symeonides M; Albin JS; Li M; Thali M; Harris RS
PLoS Pathog; 2018 Apr; 14(4):e1007010. PubMed ID: 29677220
[TBL] [Abstract][Full Text] [Related]
25. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
[TBL] [Abstract][Full Text] [Related]
26. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.
Sadler HA; Stenglein MD; Harris RS; Mansky LM
J Virol; 2010 Jul; 84(14):7396-404. PubMed ID: 20463080
[TBL] [Abstract][Full Text] [Related]
27. Human-APOBEC3G-dependent restriction of porcine endogenous retrovirus replication is mediated by cytidine deamination and inhibition of DNA strand transfer during reverse transcription.
Jin SY; Choi HY; Kim HS; Jung YT
Arch Virol; 2018 Jul; 163(7):1907-1914. PubMed ID: 29610985
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1.
Ikeda T; Molan AM; Jarvis MC; Carpenter MA; Salamango DJ; Brown WL; Harris RS
J Gen Virol; 2019 Jul; 100(7):1140-1152. PubMed ID: 31145054
[TBL] [Abstract][Full Text] [Related]
29. Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.
Neogi U; Shet A; Sahoo PN; Bontell I; Ekstrand ML; Banerjea AC; Sonnerborg A
J Int AIDS Soc; 2013 Feb; 16(1):18472. PubMed ID: 23443042
[TBL] [Abstract][Full Text] [Related]
30. Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice.
Sato K; Izumi T; Misawa N; Kobayashi T; Yamashita Y; Ohmichi M; Ito M; Takaori-Kondo A; Koyanagi Y
J Virol; 2010 Sep; 84(18):9546-56. PubMed ID: 20610708
[TBL] [Abstract][Full Text] [Related]
31. A functional conserved intronic G run in HIV-1 intron 3 is critical to counteract APOBEC3G-mediated host restriction.
Widera M; Hillebrand F; Erkelenz S; Vasudevan AA; Münk C; Schaal H
Retrovirology; 2014 Aug; 11():72. PubMed ID: 25169827
[TBL] [Abstract][Full Text] [Related]
32. Estimating the fraction of progeny virions that must incorporate APOBEC3G for suppression of productive HIV-1 infection.
Thangavelu PU; Gupta V; Dixit NM
Virology; 2014 Jan; 449():224-8. PubMed ID: 24418556
[TBL] [Abstract][Full Text] [Related]
33. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
34. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation.
Mercenne G; Bernacchi S; Richer D; Bec G; Henriet S; Paillart JC; Marquet R
Nucleic Acids Res; 2010 Jan; 38(2):633-46. PubMed ID: 19910370
[TBL] [Abstract][Full Text] [Related]
35. APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA.
Russell RA; Moore MD; Hu WS; Pathak VK
Retrovirology; 2009 Feb; 6():16. PubMed ID: 19216784
[TBL] [Abstract][Full Text] [Related]
36. APOBEC3G subunits self-associate via the C-terminal deaminase domain.
Bennett RP; Salter JD; Liu X; Wedekind JE; Smith HC
J Biol Chem; 2008 Nov; 283(48):33329-36. PubMed ID: 18842592
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
38. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.
Haché G; Shindo K; Albin JS; Harris RS
Curr Biol; 2008 Jun; 18(11):819-24. PubMed ID: 18501607
[TBL] [Abstract][Full Text] [Related]
39. APOBEC3-mediated editing in HIV type 1 from pediatric patients and its association with APOBEC3G/CUL5 polymorphisms and Vif variability.
De Maio FA; Rocco CA; Aulicino PC; Bologna R; Mangano A; Sen L
AIDS Res Hum Retroviruses; 2012 Jun; 28(6):619-27. PubMed ID: 22145963
[TBL] [Abstract][Full Text] [Related]
40. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
